アキレス腱症に対するプロロ療法
Hau Pham1, Wei Tseng1, Ewald R Mendeszoon1
1*Department of Surgery, Boston Medical Center, Boston, MA. Dr. Wong is now part of a practice group in Oceanside, CA. Dr. Hutchins is now at Whittier Street Health Center, Boston, MA, and Providence Community Health Centers, Providence, RI. Dr. Amin is now in private practice in Jacksonville, FL. Dr. Reubens is now part of a practice group in Harrisburg, PA.
Journal of the American Podiatric Medical Association
|December 30, 2025
まとめ
プロロ療法は、12ヶ月以内に74.2%の患者でアキレス腱炎を効果的に治療しました。この再生注射技術は、アキレス腱痛の緩和に有望です。
科学分野:
- 再生医療; 筋骨格系疾患; 注射療法
背景:
- プロロ療法は、再生注射技術であり、高浸透圧デキストロースを使用して組織修復を刺激します。超音波ガイド下でのアキレス腱への注射は、新しい細胞増殖と組織再生を促進します。この研究は、アキレス腱炎に対するプロロ療法の有効性を評価することを目的としました。
研究 の 目的:
- プロロ療法によるアキレス腱炎の治療反応を評価すること。アキレス腱障害の患者に対する再生注射療法の有効性を判断すること。
主な方法:
- 2014年から2017年までの非外傷性アキレス腱障害を持つ132人の参加者の後ろ向きレビュー。外傷性原因、先行する断裂、または他の腱病変の除外。症状の持続期間、プロロ療法セッション、および結果を評価する12ヶ月の追跡調査。筋骨格系放射線科医によって実施されました。
主要な成果:
- 132人の参加者のうち132人(74.2%)が12ヶ月以内に症状の改善を達成しました。プロロ療法セッション1回後、53.8%が症状の改善を経験しました。参加者の25.8%は、12ヶ月の追跡期間後も症状が残っていました。
結論:
- プロロ療法は、特に骨格変形のない患者において、アキレス腱炎に対して優れた結果を示しました。12ヶ月の研究期間中に有害事象は報告されませんでした。プロロ療法の有効性を確認するために、さらなる前向き無作為化比較試験が推奨されます。
さらに関連する動画
関連する概念動画
Skin Diseases and Disorders
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
Acne Infection
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...


